Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 4/20 | 0.40 |
| ▸ | JAK3 | P52333 | 3/20 | 0.40 |
| ▸ | JAK1 | P23458 | 2/20 | 0.40 |
| ▸ | ACACB | O00763 | 2/20 | 0.39 |
| ▸ | BCL6 | P41182 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.37 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1748798 | 0.85 | GAA (0.48) | GAAMAPTHSD17B10KDM4ELMNA | |
| SCHEMBL1749402 | 0.84 | GAA (0.47) | GAAMAPTHSD17B10KDM4ELMNA | |
| SCHEMBL1749278 | 0.84 | GAA (0.40) | GAAMAPTHSD17B10KDM4EJAK2 | |
| SCHEMBL1749232 | 0.83 | GAA (0.41) | GAAMAPTHSD17B10KDM4EJAK2 | |
| SCHEMBL1749216 | 0.83 | ALDH1A1 (0.45) | GAAMAPTLMNAACACBUSP30 | |
| SCHEMBL1749219 | 0.83 | ALDH1A1 (0.45) | GAAMAPTLMNAACACBUSP30 | |
| SCHEMBL1750144 | 0.81 | EML4 (0.43) | GAAMAPTHSD17B10KDM4EJAK3 | |
| SCHEMBL2171157 | 0.81 | ALDH1A1 (0.41) | GAAACACBMAP4K4 | |
| SCHEMBL6792109 | 0.81 | AR (0.41) | JAK2JAK3JAK1USP30MAP4K4 | |
| SCHEMBL6052098 | 0.80 | MAPT (0.53) | GAAMAPTHSD17B10KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | CYP11B2, CYP11B1, CYP1A1 | GAA 1379/4885MAPT 4824/4885HSD17B10 1208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.